AIHTA - Publications - Search - Cemiplimab (Libtayo®) as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC)

Wolf, S. (2021): Cemiplimab (Libtayo®) as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC). Oncology Fact Sheet Nr. 52.

[thumbnail of Oncology Fact Sheet Nr.52.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
103kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WF Respiratory system
Language:English
Series Name:Oncology Fact Sheet Nr. 52
Deposited on:28 Jun 2021 14:02
Last Modified:28 Jun 2021 15:28

Repository Staff Only: item control page